MRK · News · 20260826N

Oncology Portfolio Expansion

Merck & Co., Inc. · 2026-08-26 · Importance 33 · Surprise 42

Merck and Moderna reported positive Phase 3 results for their personalized mRNA-based cancer vaccine collaboration on August 26, 2026. The results strengthen the potential of the oncology pipeline to offset Keytruda’s expected patent expiration in 2028. The reports did not disclose a dollar value, regulatory filing date, or projected revenue contribution.

Key facts

• Beverly Hills Private Wealth LLC cut its stake in shares of Merck and Co., Inc. by 59.7%, owning 5,600 shares after selling 8,299 shares during the period. source
• Merck reported better-than-expected quarterly results and declared a quarterly dividend. source
• Occidental Asset Management LLC increased its stake in Merck & Co., Inc. by 24% in the second quarter, purchasing an additional 11,002 shares to bring its total holdings to 56,777 shares valued at approximately $7.3 million. source
• Insiders have sold approximately $30 million in Merck & Co., Inc. stock over the past three months. source
• Merck's shares recently rose 3.9% to $156.54, near their 52-week high. source
• Trust Co. of Vermont purchased 106,435 shares of Merck & Co., Inc. valued at approximately $13.7 million in the second quarter. source